HC Wainwright Raises Earnings Estimates for Replimune Group

Replimune Group, Inc. (NASDAQ:REPL) – Investment analysts at HC Wainwright upped their Q3 2025 earnings per share (EPS) estimates for shares of Replimune Group in a report released on Tuesday, November 12th. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.73) per share for the quarter, up from their prior forecast of ($0.79). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Replimune Group’s current full-year earnings is ($3.05) per share. HC Wainwright also issued estimates for Replimune Group’s Q4 2025 earnings at ($0.75) EPS and FY2025 earnings at ($2.93) EPS.

Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.07.

A number of other equities analysts also recently issued reports on the stock. JPMorgan Chase & Co. increased their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. Roth Mkm assumed coverage on Replimune Group in a research report on Tuesday, August 27th. They set a “buy” rating and a $17.00 target price on the stock. Finally, Roth Capital raised Replimune Group to a “strong-buy” rating in a research report on Tuesday, August 27th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus price target of $16.80.

Replimune Group Trading Down 5.3 %

NASDAQ REPL opened at $10.80 on Friday. Replimune Group has a one year low of $4.92 and a one year high of $12.97. The company has a debt-to-equity ratio of 0.18, a quick ratio of 13.46 and a current ratio of 10.11. The company has a market capitalization of $738.94 million, a price-to-earnings ratio of -3.54 and a beta of 1.19. The company’s 50-day simple moving average is $11.46 and its two-hundred day simple moving average is $9.54.

Institutional Trading of Replimune Group

A number of institutional investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC increased its position in Replimune Group by 10,304.2% during the 2nd quarter. Nisa Investment Advisors LLC now owns 4,994 shares of the company’s stock valued at $45,000 after buying an additional 4,946 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Replimune Group during the second quarter worth about $57,000. Arizona State Retirement System acquired a new position in shares of Replimune Group during the second quarter valued at about $108,000. Quest Partners LLC raised its position in shares of Replimune Group by 30.4% in the 2nd quarter. Quest Partners LLC now owns 13,510 shares of the company’s stock valued at $122,000 after purchasing an additional 3,150 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Replimune Group in the 3rd quarter valued at approximately $133,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.